Indefinite Delivery Contract SPE2DR25D2215

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain awarded a single-award Indefinite Delivery Contract (IDC) valued at $999,999,999 to AmerisourceBergen Drug Corp. to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally. This IDC, which runs through December 2036, serves as a prime vehicle for delivering critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas such as cardiovascular health, diabetes management, mental health, pain management, and infectious disease prevention. The contract was awarded through an open competition, with no set-aside requirements, to enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries. In addition to the DLA contract, AmerisourceBergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

The original solicitation, expected to be issued in March 2024, seeks to establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, United States Coast Guard, and US Naval Fleet. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. The government intends to make multiple primary supplier awards for separate regions (North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet) as well as a single backup supplier award, with the goal of having at least three different contractors to ensure resiliency and access to vital pharmaceuticals during contingencies or natural disasters.